TY - JOUR
T1 - APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing
AU - Omata, Masao
AU - Kanda, Tatsuo
AU - Wei, Lai
AU - Yu, Ming Lung
AU - Chuang, Wang Long
AU - Ibrahim, Alaaeldin
AU - Lesmana, Cosmas Rinaldi Adithya
AU - Sollano, Jose
AU - Kumar, Manoj
AU - Jindal, Ankur
AU - Sharma, Barjesh Chander
AU - Hamid, Saeed S.
AU - Dokmeci, A. Kadir
AU - Al-Mahtab, Mamun
AU - McCaughan, Geofferey W.
AU - Wasim, Jafri
AU - Crawford, Darrell H.G.
AU - Kao, Jia Horng
AU - Yokosuka, Osamu
AU - Lau, George K.K.
AU - Sarin, Shiv Kumar
N1 - Funding Information:
Alaaeldin Ibrahim, Cosmas Rinaldi Adithya Lesmana, Mamun Al-Mahtab, George K. K. Lau, Barjesh C. Sharma, Jose Sollano, Manoj Kumar, Ankur Jindal, A. Kadir Dokmeci, Geofferey W. McCaughan, Darrell H. G. Crawford, Jafri Wasim, and Shiv Kumar Sarin declare that they have no conflict of interest. Masao Omata received fees for being a speaker, consultant, and advisory board member for Bayer Co., Boehringer Ingelheim, Bristol-Myers Squibb, Otsuka, Astellas, Gilead Sciences, Chugai, Mitsubishi Tanabe, Kyorin, Merck Sharp & Dohme, Dainippon Sumitomo, Vertex Pharmaceuticals, Takeda, and Zeria. Tatsuo Kanda received lecture fees from Chugai Pharmaceutical, MSD, Tanabe-Mitsubishi, Daiichi-Sankyo, Bristol-Myers Squibb, Gilead Sciences, and AbbVie and a research grant from Chugai and MSD. Lai Wei has research grants from BMS and Roche and received consulting fees from Abbott, AbbVie, BMS, Gilead, and Novartis. Ming-Lung Yu is a consultant and advisory board member and has grant support from AbbVie, BMS, Gilead, Roche, MSD, and Abbott. Wang-Long Chuang received speaker fees from Gilead, BMS, MSD, Roche, and Novartis and is a member of the following advisory boards: Gilead, AbbVie, and Roche. Saeed S. Hamid has conference travel support from Gilead. Jia-Horng Kao has served as a consultant for AbbVie, Bristol-Myers Squibb, Gilead Sciences, and Roche and has also served on speakers’ bureaus for Roche, Bristol-Myers Squibb, Gilead Sciences, and Novartis. Osamu Yokosuka has research grants from Chugai Pharmaceutical, Bayer, MSD, Daiichi-Sankyo, Tanabe-Mitsubishi, and Bristol-Myers Squibb and received speaking fees from Merck Sharp and Dohme, Kowa Souku, Sysmex, Chugai Pharmaceutical Co., GlaxoSmithKline, Bristol-Myers Squibb, Ajinomoto-Seiyaku, Bayer, Abbott, Given Imaging, Mitsubishi Tanabe Pharm, Taiho Yakuhin, Dainippon Sumitomo Pharm, and Igaku-Seibutsugaku Institute.
Publisher Copyright:
© 2016, The Author(s).
PY - 2016/9/1
Y1 - 2016/9/1
N2 - The Asian Pacific Association for the Study of the Liver (APASL) convened an international working party on “APASL consensus statements and recommendations for management of hepatitis C” in March 2015 to revise the “APASL consensus statements and management algorithms for hepatitis C virus infection” (Hepatol Int 6:409–435, 2012). The working party consisted of expert hepatologists from the Asian–Pacific region gathered at the Istanbul Congress Center, Istanbul, Turkey on 13 March 2015. New data were presented, discussed, and debated during the course of drafting a revision. Participants of the consensus meeting assessed the quality of the cited studies. The finalized recommendations for hepatitis C prevention, epidemiology, and laboratory testing are presented in this review.
AB - The Asian Pacific Association for the Study of the Liver (APASL) convened an international working party on “APASL consensus statements and recommendations for management of hepatitis C” in March 2015 to revise the “APASL consensus statements and management algorithms for hepatitis C virus infection” (Hepatol Int 6:409–435, 2012). The working party consisted of expert hepatologists from the Asian–Pacific region gathered at the Istanbul Congress Center, Istanbul, Turkey on 13 March 2015. New data were presented, discussed, and debated during the course of drafting a revision. Participants of the consensus meeting assessed the quality of the cited studies. The finalized recommendations for hepatitis C prevention, epidemiology, and laboratory testing are presented in this review.
UR - http://www.scopus.com/inward/record.url?scp=84970004340&partnerID=8YFLogxK
U2 - 10.1007/s12072-016-9736-3
DO - 10.1007/s12072-016-9736-3
M3 - Review article
C2 - 27229718
AN - SCOPUS:84970004340
SN - 1936-0533
VL - 10
SP - 681
EP - 701
JO - Hepatology International
JF - Hepatology International
IS - 5
ER -